Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 3;5(2):304-316.
doi: 10.20517/cdr.2021.147. eCollection 2022.

Mechanisms of chemotherapy resistance in ovarian cancer

Mylena Ortiz  1   2 , Emma Wabel  1   3   2 , Kerry Mitchell  1   2 , Sachi Horibata  1   3
Affiliations
Review

Mechanisms of chemotherapy resistance in ovarian cancer

Mylena Ortiz et al. Cancer Drug Resist. .

Abstract

Ovarian cancer is one of the most lethal gynecologic cancers. The standard therapy for ovarian cancer has been the same for the past two decades, a combination treatment of platinum with paclitaxel. Recently, the FDA approved three new therapeutic drugs, two poly (ADP-ribose) polymerase inhibitors (olaparib and niraparib) and one vascular endothelial growth factor inhibitor (bevacizumab) as maintenance therapies for ovarian cancer. In this review, we summarize the resistance mechanisms for conventional platinum-based chemotherapy and for the newly FDA-approved drugs.

Keywords: Drug resistance; bevacizumab; carboplatin; cisplatin; niraparib; olaparib; ovarian cancer; paclitaxel.

PubMed Disclaimer

Conflict of interest statement

All authors declared that there are no conflicts of interest.

Figures

Figure 1
Figure 1
Schematic illustration of platinum resistance.
Figure 2
Figure 2
Schematic illustration of paclitaxel resistance.
Figure 3
Figure 3
Schematic illustration of PARPi resistance. PARPi: Olymerase inhibitor.
Figure 4
Figure 4
Schematic illustration of VEGFi resistance. VEGFi: Vascular endothelial growth factor inhibitor.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33. doi: 10.3322/caac.21654. - DOI - PubMed
    1. Damia G, Broggini M. Platinum resistance in ovarian cancer: role of DNA repair. Cancers (Basel) 2019;11:119. doi: 10.3390/cancers11010119. - DOI - PMC - PubMed
    1. Rosenberg B, Vancamp L, Krigas T. Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode. Nature. 1965;205:698–9. doi: 10.1038/205698a0. - DOI - PubMed
    1. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7:573–84. doi: 10.1038/nrc2167. - DOI - PubMed
    1. Harrap K. Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treatment Reviews. 1985;12:21–33. doi: 10.1016/0305-7372(85)90015-5. - DOI - PubMed

LinkOut - more resources